Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
Qelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT2C) pharmacodynamics approved in its FDA product…
Read the full articleYou might also wanna read
FDA Set to Decide on a New Non-Stimulant ADHD Drug for Children and Adults on July 24
FDA decides on centanafadine July 24, 2026 — a first-in-class non-stimulant ADHD drug for children, adolescents, and adults. Four Phase 3 tr
FDA Explores Expediting Clinical Trials: Announces Ambitious New Drug Pilot Program
On June 24, 2026, the Food and Drug Administration (FDA) published a notice of availability in the Federal Register requesting information a
CME | Stimulants & Strategy: Integrating ADHD Treatments Into Daily Practice
In this episode of CME on the go, recorded live at FMX in Anaheim, our hosts discuss the complexities of ADHD treatment. They cover initial
CME | Focus Forward: Navigating ADHD Across the Lifespan
The CME on the Go series of the Inside Family Medicine podcast lets you earn up to 0.5 CME credits per episode — join the hosts as they dive
Lisdexanfetamine and its biomedical effects and neurophysiological implications in university students: A systematic review
This study aimed to analyze the biomedical effects and neurophysiological implications of lisdexamfetamine in university students, with an e
Tylenol autism lawsuits revived by federal appeals court
A federal appeals court has revived more than 500 private lawsuits alleging that Tylenol use during pregnancy contributed to autism and atte
Comments
Sign in to join the conversation.
No comments yet. Be the first.